CIMERLI® Business Archives

Sandoz Acquires CIMERLI® Business from Coherus, Further Building Biosimilar and Ophthalmology Leadership in US Market

CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab injection) for all approved indications Dedicated retina sales and field reimbursement team integrated into Sandoz, ensuring seamless experience for providers and patients Basel, March 4, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, has completed the acquisition of the US biosimilar CIMERLI®* [...]

Sandoz Announces Agreement to Acquire CIMERLI® Business from Coherus, Strengthening Position in US Market

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®** (ranibizumab-injection) for all approved indications Acquisition strengthens Sandoz ophthalmology portfolio Basel, January 22, 2024 (Korea Bizwire) – Sandoz, the global leader in generic and biosimilar medicines, has signed an agreement to acquire the US [...]